Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mauna Kea Technologies's annualizedNet Income for the quarter that ended in Dec. 2025 was €30.88 Mil. Mauna Kea Technologies's average total tangible assets for the quarter that ended in Dec. 2025 was €11.95 Mil. Therefore, Mauna Kea Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 258.47%.
The historical rank and industry rank for Mauna Kea Technologies's Return-on-Tangible-Asset or its related term are showing as below:
STU:1MK'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -77.91 Med: -58.21 Max: 83.57
Current: 83.57
During the past 13 years, Mauna Kea Technologies's highest Return-on-Tangible-Asset was 83.57%. The lowest was -77.91%. And the median was -58.21%.
STU:1MK's Return-on-Tangible-Asset is ranked better than 99.3% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.81
vs STU:1MK: 83.57
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Mauna Kea Technologies Return-on-Tangible-Asset Related Terms
Mauna Kea Technologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Mauna Kea Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1MK vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Mauna Kea Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mauna Kea Technologies Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Mauna Kea Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 258.47% mean?
Mauna Kea Technologies (STU:1MK) has a Return-on-Tangible-Asset of 258.47% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mauna Kea Technologies and its competitors. According to the industry distribution chart, Mauna Kea Technologies ranks #6 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 0.7%.
Is Mauna Kea Technologies' Return-on-Tangible-Asset too high?
Mauna Kea Technologies' current Return-on-Tangible-Asset is 258.47%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.81. Mauna Kea Technologies' value of 258.47% is 31809.9% above this industry median. Based on the distribution chart, Mauna Kea Technologies ranks #6 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Mauna Kea Technologies has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mauna Kea Technologies ranks #6 out of 853 companies for Return-on-Tangible-Asset. This places Mauna Kea Technologies in the top 1% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.81. Mauna Kea Technologies' value of 258.47% is 31809.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.81, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mauna Kea Technologies's current Return-on-Tangible-Asset of 258.47% is 31809.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mauna Kea Technologies and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mauna Kea Technologies's current Return-on-Tangible-Asset is 258.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (STU:1MK) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.15 — trading 13.4% above its estimated fair value. The current Return-on-Tangible-Asset is 258.47% and 31809.9% above the Medical Devices & Instruments industry median of 0.81. Mauna Kea Technologies' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Mauna Kea Technologies (STU:1MK), the current Return-on-Tangible-Asset is 258.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (STU:1MK) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.15 is trading 13.4% above its estimated GF Value™ of €0.13.
GuruFocus considers Mauna Kea Technologies to be Modestly Overvalued.
Key valuation signals for STU:1MK:
Return-on-Tangible-Asset: 258.47%
GF Value™: €0.13 vs. price of €0.15 (13.4% above fair value)
Industry Position: 31809.9% above the Medical Devices & Instruments median (#6 of 853)
No single metric tells the full story. See the STU:1MK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
47GF Score
Get the complete analysis for STU:1MK
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1MK has been successfully added to your 
